Arbutus Biopharma Corporation (NASDAQ:ABUS) Q3 2022 Earnings Conference Call January 1, 2022 8:45 AM ET

Company Participants

Lisa Caperelli - Vice President of Investor Relations

Bill Collier - President and Chief Executive Officer

David Hastings - Chief Financial Officer

Gaston Picchio - Chief Development Officer

Mike Sofia - Chief Scientific Officer

Conference Call Participants

Dennis Ding - Jefferies

Roy Buchanan - JMP

Keay Nakae - Chardan

Operator

Good day. And thank you for standing by, and welcome to Arbutus Biopharma Corporation's 2022 Third Quarter Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Lisa Caperelli, Vice President of Investor Relations. You may begin.

Lisa Caperelli

Thanks, Justin. Good morning, everyone, and thank you for joining Arbutus' third quarter 2022 financial results and corporate update call. Joining me today from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; David Hastings, Chief Financial Officer; Dr. Gaston Picchio, Chief Development Officer; and Dr. Mike Sofia, Chief Scientific Officer.

Bill will begin with a corporate update, followed by Dave, who will provide a review of the company's third quarter 2022 financial results. After opening remarks, we will open the call for Q&A. Gaston and Mike will be available to address clinical development and research-related questions.

Before we begin, I'd like to remind you that some of the statements made during the call today are forward-looking statements, which are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in our most recent annual report on 10-K, quarterly report on Form 10-Q to be filed later today, and from time to time in other documents filed with the SEC.

With that, I'll turn the call over to Bill Collier. Bill?

Bill Collier

Thank you, and thank you everyone for joining us today. We really do appreciate your continued interest and support of Arbutus Biopharma.

Now, this morning we issued our third quarter 2022 financial results and corporate update press release, which highlights the significant progress we have made in advancing our preclinical and clinical programs in support of our mission to develop a functional cure for hepatitis B virus, and to treat COVID-19 and future corona virus outbreaks.